Cellosaurus logo
expasy logo

Cellosaurus WM35 (CVCL_0580)

[Text version]
Cell line name WM35
Synonyms WM-35; WM 35; WC00060
Accession CVCL_0580
Resource Identification Initiative To cite this cell line use: WM35 (RRID:CVCL_0580)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: Wistar Institute melanoma cell line collection.
Population: Caucasian.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Transcriptome analysis by microarray.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: D18S51: 20->14,15 and FGA: 19->19,24.
Derived from site: In situ; Skin; UBERON=UBERON_0002097.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=18632627; Cosmic-CLP=1299080; DepMap=ACH-002207; Wistar).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North0.26
East Asian, South0.38
South Asian0.25
European, North72.7
European, South26.42
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A806 (WM35-P1N1)CVCL_A807 (WM35-P1N2)CVCL_A808 (WM35-P1N3)
CVCL_A809 (WM35-P2N1)CVCL_A810 (WM35-P2N2)CVCL_A811 (WM35-P2N3)
Sex of cell Female
Age at sampling 24Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-2807; Cosmic-CLP=1299080; PubMed=27087056; Wistar

Markers:
AmelogeninX
CSF1PO10
D2S133818,25
D3S135816,18
D5S81811,12
D7S82010,13
D8S117911,13
D13S31711
D16S53912,13
D18S5114,15
D19S43315,16
D21S1129,32.2
FGA19,24
TH019.3
TPOX8
vWA17

Run an STR similarity search on this cell line
Web pages https://web.archive.org/web/20141129125241/http://www.wistar.org:80/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-0
Publications

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028; PMCID=PMC52015
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

PubMed=8160777; PMCID=PMC1887247
Kobayashi H., Man S., MacDougall J.R., Graham C.H., Lu C., Kerbel R.S.
Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype.
Am. J. Pathol. 144:776-786(1994)

PubMed=11123321; DOI=10.4049/jimmunol.166.1.432
Li J., Pereira S., Van Belle P., Tsui P., Elder D.E., Speicher D.W., Deen K., Linnenbach A., Somasundaram R., Swoboda R.K., Herlyn D.
Isolation of the melanoma-associated antigen p23 using antibody phage display.
J. Immunol. 166:432-438(2001)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235; PMCID=PMC2615688
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431; PMCID=PMC2651569
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012)

PubMed=27087056; DOI=10.1038/srep24569; PMCID=PMC4834532
Haridas P., McGovern J.A., Kashyap A.S., McElwain D.L.S., Simpson M.J.
Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line.
Sci. Rep. 6:24569-24569(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2807 - Discontinued
Coriell; WC00060 - Discontinued
Cell line databases/resources CLO; CLO_0009617
MCCL; MCC:0000486
cancercelllines; CVCL_0580
Cell_Model_Passport; SIDM00974
Cosmic-CLP; 1299080
DepMap; ACH-002207
LINCS_LDP; LCL-1263
Lonza; 583
Anatomy/cell type resources BTO; BTO:0003475
Biological sample resources BioSample; SAMN03471793
Chemistry resources GDSC; 1299080
PharmacoDB; WM35_1672_2019
Encyclopedic resources Wikidata; Q54994256
Experimental variables resources EFO; EFO_0022558
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM109040
GEO; GSM186484
GEO; GSM186485
GEO; GSM188068
GEO; GSM188120
GEO; GSM188193
GEO; GSM188208
GEO; GSM188213
GEO; GSM188284
GEO; GSM188293
GEO; GSM555119
GEO; GSM555188
GEO; GSM952586
GEO; GSM1670580
Polymorphism and mutation databases Cosmic; 686396
Cosmic; 886834
Cosmic; 1155548
Cosmic; 1187584
Cosmic; 1247866
Cosmic; 1303075
Cosmic; 1507600
Cosmic; 1995666
Cosmic; 2159431
Progenetix; CVCL_0580
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number34